John Heymach, MD, PhD
Advertisement
Articles by John Heymach, MD, PhD
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
Advertisement
Latest Updated Articles
Improved Outcomes for Patients With EGFR+ NSCLCMay 21st 2020
Molecular Testing for Newly Diagnosed NSCLCMay 21st 2020
Repeat Testing at Progression of EGFR+ NSCLCMay 21st 2020
Treatment Options for EGFR+ NSCLCMay 21st 2020
Changing Landscape of EGFR+ mNSCLCMay 21st 2020
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Switching From Chemoimmunotherapy When a ROS1 Result Returns
2
Building an Adequate ROS1 Workup With RNA-Based Sequencing
3
Etentamig Improves Response, Survival in Phase 3 Trial for Relapsed/Refractory Myeloma
4
CAR T-Cell Therapy Delivers Durable QOL Gains at 2 Years
5